Redeye comments on Sleep Cycle’s Capital Markets Day (CMD), including the revised financial targets.
Guides for 34-42% FY'24 ARR growth (vs. ABGSCe at 30%) No outlook comments - we await the annual rep...
The recent scientific paper in Neurotherapeutics discusses the encouraging preclinical studies focus...
ARR and P&L headline items known, FCF better vs. ABGSCe FY'24 guidance reiterated (as expected) Expe...
Redeye comments on MGI’s record sales figures for February, representing an organic growth of 25%, u...
To be entitled to profit sharing for 2023 you can not be a part of any variable pay program, you mus...
Kapsaicinproducenten XP Chemistries har lämnat in sin Feed additive-ansökan till EFSA (European Food...
As expected, IOVaxis excercised the option to license TG01 in Greater China.
Redeye leaves a comment following the recently announced updated data from the BEXMAB study with the...
Equity analyst Markus Almerud follows up on Maha Energy after the purchase of 3R and the suggested r...
EGM in 3R Petroleum the next step in transformation Over the past year, Maha has continued to transf...
Redeye updates its estimates following Artificial Solutions' Q4 2023 report.
ChargePanel publicerade den 18 mars år 2024 bolagets delårsrapport för det fjärde kvartal 2023.
Carbiotix AB (”Carbiotix” eller Bolaget”) har under inledningen av år 2024 erhållit GRAS SA-godkänna...
Today, I-Tech announced a new customer agreement with the US paint manufacturer PPG.
New customer (PPG) launches Selektope-paint for the global market 4 out of ~9 relevant customers now...
CirChem har nyligen presenterat sin Q4-rapport där vi vill betona att det faktum att CirChem lyckas ...
Biovica continues to advance DiviTum among clinical users, but the absolute sales levels are still m...
Redeye comments on Sivers' product announcement, initally worth USD1.
God tillväxt för 2023 med bra kostnadskontroll Som väntat blev 2023 ett rekordår för Redsense omsät...
